SHINE Technologies, UW-Madison, and WARF Partner on New Kidney and Prostate Cancer Treatments

SHINE Technologies, a forward-thinking fusion enterprise, together with WARF Therapeutics, the drug discovery initiative by the Wisconsin Alumni Research Foundation, have shared encouraging pre-clinical research outcomes. These advancements come from their collaboration with the Advanced Radiotheranostics Lab at the University of Wisconsin-Madison.

The research highlights two novel treatments: WT-7695 and ART-101. WT-7695, a radiopharmaceutical developed by WARF Therapeutics, employs SHINE's Ilumira and has demonstrated outstanding results, achieving 100% survival in a kidney cancer model. Meanwhile, ART-101, a new prostate cancer therapy from the Advanced Radiotheranostics Lab, also uses Ilumira and has shown to be more effective than existing treatments.

SHINE Technologies and WARF Therapeutics have leveraged SHINE's cutting-edge non-carrier added lutetium-177 (Lu-177) chloride, known as Ilumira, in both of these groundbreaking treatments. Their findings suggest significant potential for extending patient survival and enhancing treatment effectiveness for both kidney and prostate cancers.

Working closely with principal investigators from both the University of Wisconsin-Madison and the Morgridge Institute for Research, WARF Therapeutics is creating a translational research pathway. This approach integrates globally recognized research with an industry-centered strategy to enhance the value propositions of emerging drug candidates.

These promising developments underscore the potential impact of combining advanced fusion technology with pioneering drug discovery efforts in the fight against cancer.